Adverum Biotechnologies, Inc. (ADVM) Financial Statements (2026 and earlier)

Company Profile

Business Address 100 CARDINAL WAY
REDWOOD CITY, CA 94063
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2025
MRQ
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:125,70096,500185,600305,200429,729166,035
Cash and cash equivalent60,65275,00068,43134,19562,42465,897
Short-term investments 65,03921,526117,158270,993367,305100,138
Other undisclosed cash, cash equivalents, and short-term investments9(26)1112  
Other undisclosed current assets5,6006,2734,99511,9454,7099,835
Total current assets:131,300102,773190,595317,145434,438175,870
Noncurrent Assets
Operating lease, right-of-use asset33,61152,26678,93486,00019,37620,963
Property, plant and equipment11,60714,76434,92733,06027,72524,884
Restricted cash and investments1,9761,9762,5032,503999999
Other noncurrent assets1,3471,2311,4132502911
Other undisclosed noncurrent assets    769  
Total noncurrent assets:48,54170,237117,777122,58248,12946,857
TOTAL ASSETS:179,841173,010308,372439,727482,567222,727
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities12,82911,13812,15114,48113,55413,401
Taxes payable1,318  
Employee-related liabilities9,2098,3444,055
Accounts payable1,6101,9212,2381,3872,8104,103
Accrued liabilities11,2199,2179,9132,5672,4005,243
Debt     4,4734,034
Other undisclosed current liabilities10,06913,77620,0956,8392,8441,973
Total current liabilities:22,89824,91432,24621,32020,87119,408
Noncurrent Liabilities
Long-term debt and lease obligation:    101,10826,23528,214
Liabilities, other than long-term debt86,22964,62794,6081,1141,114148
Other liabilities192 1,0471,1141,114148
Operating lease, liability86,03764,62793,561101,10826,23528,214
Total noncurrent liabilities:86,22964,62794,608102,22227,34928,362
Total liabilities:109,12789,541126,854123,54248,22047,770
Equity
Equity, attributable to parent70,71483,469181,518316,185434,347174,957
Common stock2101010107
Additional paid in capital1,138,0701,003,709985,651964,965937,134560,704
Accumulated other comprehensive loss(407)(473)(1,531)(714)(261)(725)
Accumulated deficit(1,066,951)(919,777)(802,612)(648,076)(502,536)(385,029)
Total equity:70,71483,469181,518316,185434,347174,957
TOTAL LIABILITIES AND EQUITY:179,841173,010308,372439,727482,567222,727

Income Statement (P&L) ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues 1,0003,600 7,500 250
Sublease income   (300)1,200  
Gross profit: 1,0003,600 7,500 250
Operating expenses(140,159)(127,591)(157,135)(153,622)(117,950)(68,795)
Other undisclosed operating income   300   
Operating loss:(139,159)(123,991)(157,135)(146,122)(117,950)(68,545)
Nonoperating income8,2325,7482,6735821,5574,059
Loss, foreign currency transaction, before tax     (342) 
Other nonoperating income8,232     
Loss from continuing operations before income taxes:(130,927)(118,243)(154,462)(145,540)(116,393)(64,486)
Income tax expense (benefit)  1,078(74) (1,114) 
Loss from continuing operations:(130,927)(117,165)(154,536)(145,540)(117,507)(64,486)
Loss before gain (loss) on sale of properties:(145,540)(117,507)(64,486)
Net loss available to common stockholders, diluted:(130,927)(117,165)(154,536)(145,540)(117,507)(64,486)

Comprehensive Income ($ in thousands)

9/30/2025
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net loss:(130,927)(117,165)(154,536)(145,540)(117,507)(64,486)
Comprehensive loss:(130,927)(117,165)(154,536)(145,540)(117,507)(64,486)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent661,058(817)(453)46474
Comprehensive loss, net of tax, attributable to parent:(130,861)(116,107)(155,353)(145,993)(117,043)(64,412)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: